Proxy Results (Form 8-K)

On June 23, 2026, Orchestra BioMed Holdings, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting"). A total of 59,880,715 shares of the Company's common stock, par value $0.0001 per share ("Common Stock"), were entitled to vote as of April 28, 2026, the record date for the Annual Meeting. There were 49,053,298 shares of Common Stock represented at the Annual Meeting, at which the Company's stockholders were asked to vote on five proposals, each of which is described in more detail in the Company's definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 29, 2026 (the "Proxy Statement"). Set forth below are the matters acted upon by the Company's stockholders, and the final voting results of each such proposal.

Proposal No. 1: Election of Directors

Votes regarding the election of the three Class III director nominees were as follows:

Based on the votes set forth above, the Company's stockholders elected each of the three nominees set forth above to serve as a Class III director of the Company until the Company's 2029 annual meeting of stockholders and until such director's respective successor is duly elected and qualified.

Proposal No. 2: Ratification of Appointment of Independent Registered Public Accounting Firm

The proposal to ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2026 (the "Auditor Ratification Proposal"), received the following votes:

Based on the votes set forth above, the Auditor Ratification Proposal was approved.

Proposal No. 3: Approval of the Orchestra BioMed Holdings, Inc. 2026 Employee Stock Purchase Plan

The proposal to approve the Orchestra BioMed Holdings, Inc. 2026 Equity Incentive Plan (the "ESPP Proposal") received the following votes:

Based on the votes set forth above, the ESPP Proposal was approved.

Proposal No. 4: Advisory, Non-Binding Vote on the Compensation of the Company's Named Executive Officers

The advisory (non-binding) vote on the compensation of the Company's named executive officers (the "NEOs"), as set forth in the Proxy Statement, received the following votes: